Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 15/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

67%

4 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed trials have results

Key Signals

3 recruiting1 with results

Enrollment Performance

Analytics

Phase 4

3(50.0%)

N/A

2(33.3%)

Phase 3

1(16.7%)

6Total

Phase 4(3)

N/A(2)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT06791525Phase 4Recruiting

Tirbanibulin for Pediatric Warts

Role: lead

NCT07396168Phase 4Recruiting

Nemolizumab to Treat Lichen Planopilaris, a Noncontrolled, Prospective, Pilot Study.

Role: lead

NCT05937672Phase 3Recruiting

Cold Atmospheric Plasma Device Extension Study

Role: collaborator

NCT05592548Not ApplicableCompleted

Rosacea Treatment Using Non-thermal (cold) Atmospheric Plasma Device

Role: lead

NCT05070754Phase 4Completed

Cold Atmospheric Plasma Device for Pediatric Molluscum and Verruca

Role: collaborator

NCT02759900Not ApplicableUnknown

Using a Cold Atmospheric Plasma Device to Treat Skin Disorders

Role: lead

All 6 trials loaded